
Summit Therapeutics (SMMT) Stock Forecast & Price Target
Summit Therapeutics (SMMT) Analyst Ratings
Bulls say
Summit Therapeutics Inc. is positioned favorably in the biopharmaceutical sector, particularly with its CDI product candidate, ridinilazole, and additional promising developments in oncology. The company is likely to experience significant financial benefits from successful Phase 3 trials, with projected improvements in progression-free survival (PFS) and overall survival (OS) that could match or exceed successful market incumbents. The robust efficacy of its pipeline drugs, supported by strong statistical analysis and comparisons to leading therapies such as KEYTRUDA, underlines a positive outlook for potential sales growth and market share expansion.
Bears say
The analysis of Summit Therapeutics Inc. reflects a negative outlook primarily due to the potential marginal clinical efficacy or safety concerns related to its product Ivo, resulting in a lowered probability of success to 20%. Additionally, the company faces significant challenges from a lack of differentiated clinical data and the possibility of competition from approved drugs, which could severely impact the sales potential of its offerings. Lastly, regulatory risks and projected financial losses, including an estimated net loss of $0.32 per share, compound concerns about the viability of Summit Therapeutics's future performance.
This aggregate rating is based on analysts' research of Summit Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Summit Therapeutics (SMMT) Analyst Forecast & Price Prediction
Start investing in Summit Therapeutics (SMMT)
Order type
Buy in
Order amount
Est. shares
0 shares